Genmab — December 2020
-
-
A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab https://clinicaltrials.gov/ct2/show/NCT04667117?term=genmab+OR+daratumumab+OR+darzalex+OR+ofatumumab+OR+Teprotumumab+OR+Tisotumab+OR+camidanlumab+OR+Enapotamab+OR+ADCT-301+OR+duobody+OR+hexabody+OR+Teclistamab+OR+Amivantamab+OR+Talquetamab+OR+Epcoritamab+OR+DuoHexabody&lupd_s=12%2F12%2F2020&draw=2&rank=1
-
Not long ago it was published in some MS-news that Ocrevus might have this issue with loss of vaccinal immunity. I assume that's why Novartis wants to find out whether that goes for ofa as well. Would not be good. Especially if it is also an issue with the corona vaccines.
-
But evidence shows that some patients given vaccines to protect against the influenza virus or pneumococcal bacteria lose such immunity after Ocrevus treatment. https://multiplesclerosisnewstoday.com/news-posts/2020/08/21/ocrevus-eliminates-vaccine-immunity-to-varicella-zoster-virus-rrms-patient-case-report/
-
Novo invests in Hemab @endpointsnews https://endpts.com/novo-invests-in-hemab-a-company-going-against-the-hemophilia-gene-therapy-grain-with-a-plan-for-bispecifics/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind